AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Tagrisso improved patient outcomes in early-stage disease in the ADAURA phase III trial, Stage III, unresectable disease in the LAURA phase III trial, late-stage disease in the FLAURA phase III trial, ...

The US regulator has approved the drug after a priority review on the strength of data from the FLAURA 2 study showing that the combination of EGFR inhibitor Tagrisso (osimertinib) and chemo cut ...

AstraZeneca has been emphasising the potential of Tagrisso (osimertinib) in recent months, and the FLAURA trial backs up its claims, showing a leap forward in progression free survival (PFS ...

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

Tagrisso in the treatment of certain type of lung cancer. The study, called MARIPOSA, showed that at three years of treatment ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of ...

In 2023, TAGRISSO® plus ORPATHYS® received Fast Track designation from the US Food and Drug Administration (FDA) in this setting. ORPATHYS® is an oral, potent, and highly selective MET tyrosine ...